Restriction/Criteria for Use

• High risk of ASCVD with documented history of one of the following: Myocardial infarction, Acute coronary syndromes, Coronary artery disease, Stable or unstable angina, Coronary or other arterial revascularization, Stroke and Transient ischemic attack (not related to embolic phenomenon due to atrial fibrillation), Peripheral arterial disease

OR

• HeFH as confirmed by: World Health Organization (WHO)/Dutch Lipid Network Criteria with score of greater than 8 points, Diagnosis per Simon Broome criteria

AND one of the following

• Patient has been adherent to ezetimibe used concomitantly with a statin at a maximally tolerated dose for at least 4 months unless contraindicated
• Prescribed in conjunction with a statin at the maximally tolerated dose for at least 4 months in patients who have failed to achieve their LDL-C goal
• Patient has inability to tolerate at least 2 high-intensity statins due to adverse events (statin-associated muscle symptoms) or contraindication
• Patient has allergic responses to both evolomumab (Repatha) and alirocumab (Praluent) or have difficulty using a pen injector due to arthritis and/or weakness of the hands
• Patient has been non-compliant with statin therapy or PCSK-9 injections 

• UpToDate
• Lexicomp
• DailyMed Package Inserts
• Johns Hopkins Guides